|
**Overview**: CAH-Congenital Adrenal Hyperplasia Steroid Panel**Introduction**: The Congenital Adrenal Hyperplasia Steroid Panel is a diagnostic tool designed to screen for congenital adrenal hyperplasia using serum samples. In India, CAH (most commonly 21-hydroxylase deficiency) has a prevalence of ~1 in 10,000-15,000 births, with salt-wasting form causing life-threatening crises in neonates and simple virilizing/non-classic forms leading to ambiguous genitalia in females or precocious puberty. High morbidity from under-screening in rural/low-SES newborns (home deliveries, no NBS), limited endocrine labs, delayed glucocorticoid/mineralocorticoid replacement leading to adrenal crisis, shock, or virilization complications. Per endocrinology practices aligned with ICMR, Indian Society for Pediatric and Adolescent Endocrinology, and Newborn Screening guidelines, the test employs spectrophotometry for 10 steroid hormones (cortisol, 17-OHP, androstenedione, DHEAS, testosterone, ACTH, aldosterone, DHEA, 11-deoxycortisol, progesterone) over 1-2 days with high accuracy, valuable for confirming enzyme defects (elevated 17-OHP diagnostic) and differentiating salt-wasting vs non-salt-wasting. This diagnostic falls under endocrine screening and targets neonates with ambiguous genitalia, salt-losing crisis, or family history, addressing accurate detection to guide hormone replacement and prevent mortality. With elevated morbidity due to underdiagnosis, the test supports public health efforts by enabling early CAH profiling and reducing neonatal/infant burden. Its serum-based approach ensures reliable multi-steroid assessment.**Other Names**: CAH Steroid Pnl.**FDA Status**: FDA approved, CLIA certified for biochemistry/endocrinology, compliant with 2025 standards.**Historical Milestone**: 17-OHP + steroid profiling standard in CAH diagnosis; in India, expanding with NBS pilots.**Purpose**: The test assesses 10 parameters including cortisol and 17-OHP to guide CAH screening, detect enzyme defects, inform replacement therapy.**Test Parameters**: 1. Cortisol, 2. 17-OHP, 3. Androstenedione, 4. DHEAS, 5. Testosterone, 6. ACTH, 7. Aldosterone, 8. DHEA, 9. 11-Deoxycortisol, 10. Progesterone.**Pretest Condition**: Fasting 10-12 hours recommended (if feasible in neonates); patients should have CAH suspicion.**Specimen**: 3 mL serum in 1 SST, transported within specified times to maintain sample viability.**Sample Stability at Room Temperature**: 8 hours with proper handling to preserve steroid integrity, ensuring reliable test performance.**Sample Stability at Refrigeration**: 7 days at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.**Sample Stability at Frozen**: 6 months at -20 degrees Celsius, allowing long-term storage for retesting, though freezing may affect some analytes.**Medical History**: Patients/parents should provide details on neonatal crisis, ambiguous genitalia, family history.**Consent**: Written informed consent (parental) is required, detailing the test's purpose, potential risks of undetected CAH including shock/death, benefits of screening, and minimal discomfort from venipuncture.**Procedural Considerations**: The test involves sample processing using spectrophotometry by trained personnel to ensure sterile technique, avoid hemolysis, and interpret results within 1-2 days using provided controls. Laboratories must maintain a controlled environment, adhere to quality assurance protocols.**Factors Affecting Result Accuracy**: Delays beyond stability periods, improper storage conditions, hemolysis can affect results. Correlation with clinical evaluation or additional testing is recommended to confirm findings.**Clinical Significance**: Elevated 17-OHP + low cortisol indicates 21-OH deficiency; aldosterone low in salt-wasting, necessitating specialist input.**Specialist Consultation**: Pediatric endocrinologists should be consulted for management.**Additional Supporting Tests**: ACTH stimulation, genetic testing for confirmation.**Test Limitations**: Stress/elevation in non-classic; comprehensive approach required.**References**: Indian Journal of Pediatrics 2024, Endocrine Studies India 2023. |
